Found: 111
Select item for more details and to access through your institution.
Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
- Published in:
- Theranostics, 2024, v. 14, n. 9, p. 3693, doi. 10.7150/thno.96944
- By:
- Publication type:
- Article
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT.
- Published in:
- EJNMMI Physics, 2024, v. 11, n. 1, p. 1, doi. 10.1186/s40658-024-00636-0
- By:
- Publication type:
- Article
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2024, v. 9, n. 1, p. 1, doi. 10.1186/s41181-024-00239-1
- By:
- Publication type:
- Article
The Balance Between the Therapeutic Efficacy and Safety of [<sup>177</sup>Lu]Lu-NeoB in a Preclinical Prostate Cancer Model.
- Published in:
- Molecular Imaging & Biology, 2024, v. 26, n. 1, p. 114, doi. 10.1007/s11307-023-01851-4
- By:
- Publication type:
- Article
Evaluation of the tolerability and safety of [<sup>225</sup>Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-11900-y
- By:
- Publication type:
- Article
How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 51, n. 1, p. 3, doi. 10.1007/s00259-023-06389-9
- By:
- Publication type:
- Article
Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection.
- Published in:
- EJNMMI Physics, 2023, v. 10, n. 1, p. 1, doi. 10.1186/s40658-023-00589-w
- By:
- Publication type:
- Article
Urinary excretion kinetics of [<sup>177</sup>Lu]Lu-PSMA-617.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 12, p. 3572, doi. 10.1007/s00259-023-06328-8
- By:
- Publication type:
- Article
Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 9, p. 2595, doi. 10.1007/s00259-023-06215-2
- By:
- Publication type:
- Article
Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT).
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 9, p. 2830, doi. 10.1007/s00259-023-06255-8
- By:
- Publication type:
- Article
[ 212 Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 7, p. 985, doi. 10.3390/ph16070985
- By:
- Publication type:
- Article
First preclinical evaluation of [<sup>225</sup>Ac]Ac-DOTA-JR11 and comparison with [<sup>177</sup>Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2023, v. 8, n. 1, p. 1, doi. 10.1186/s41181-023-00197-0
- By:
- Publication type:
- Article
Efficacy and safety of peptide receptor radionuclide therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 4, p. 1195, doi. 10.1007/s00259-022-06044-9
- By:
- Publication type:
- Article
[<sup>111</sup>In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 3, p. 892, doi. 10.1007/s00259-022-05992-6
- By:
- Publication type:
- Article
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation.
- Published in:
- EJNMMI Research, 2023, v. 13, n. 1, p. 1, doi. 10.1186/s13550-023-00952-z
- By:
- Publication type:
- Article
An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Safety of [<sup>177</sup>Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 13, p. 4440, doi. 10.1007/s00259-022-05926-2
- By:
- Publication type:
- Article
Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 13, p. 4705, doi. 10.1007/s00259-022-05902-w
- By:
- Publication type:
- Article
Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.263802
- By:
- Publication type:
- Article
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 11, p. 3627, doi. 10.1007/s00259-022-05821-w
- By:
- Publication type:
- Article
Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.263802
- By:
- Publication type:
- Article
Effect of epigenetic treatment on SST<sub>2</sub> expression in neuroendocrine tumour patients.
- Published in:
- Clinical & Translational Medicine, 2022, v. 12, n. 7, p. 1, doi. 10.1002/ctm2.957
- By:
- Publication type:
- Article
Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.122.263802
- By:
- Publication type:
- Article
Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.122.263802
- By:
- Publication type:
- Article
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 6, p. 1778, doi. 10.1007/s00259-022-05727-7
- By:
- Publication type:
- Article
<sup>89</sup>Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 6, p. 2064, doi. 10.1007/s00259-021-05661-0
- By:
- Publication type:
- Article
Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.122.263802
- By:
- Publication type:
- Article
Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188 Re-ZHER2:41071.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 5, p. 1092, doi. 10.3390/pharmaceutics14051092
- By:
- Publication type:
- Article
Exploring the translational challenge for medical applications of ionising radiation and corresponding radiation protection research.
- Published in:
- 2022
- By:
- Publication type:
- journal article
[<sup>68</sup>Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [<sup>177</sup>Lu]Lu-PSMA-617 treatment.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 4, p. 1101, doi. 10.1007/s00259-021-05538-2
- By:
- Publication type:
- Article
[<sup>68</sup>Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [<sup>177</sup>Lu]Lu-PSMA-617 treatment.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 4, p. 1101, doi. 10.1007/s00259-021-05538-2
- By:
- Publication type:
- Article
Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.122.263802
- By:
- Publication type:
- Article
Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.122.263802
- By:
- Publication type:
- Article
Intra-therapeutic dosimetry of [<sup>177</sup>Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 2, p. 460, doi. 10.1007/s00259-021-05471-4
- By:
- Publication type:
- Article
Dosimetry for Radiopharmaceutical Therapy: The European Perspective.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, p. 73S, doi. 10.2967/jnumed.121.262754
- By:
- Publication type:
- Article
The limits of the "holy gray" in radioembolization and beyond: Beyond the "holy Gray".
- Published in:
- 2021
- By:
- Publication type:
- Editorial
GRPr antagonist <sup>68</sup>Ga‐SB3 PET/CT‐imaging of primary prostate cancer in therapynaive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
Modeling early radiation DNA damage occurring during [177Lu]Lu-DOTA-[Tyr3 ]octreotate radionuclide therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262610
- By:
- Publication type:
- Article
EANM dosimetry committee series on standard operational procedures: a unified methodology for <sup>99m</sup>Tc-MAA pre- and <sup>90</sup>Y peri-therapy dosimetry in liver radioembolization with <sup>90</sup>Y microspheres.
- Published in:
- EJNMMI Physics, 2021, v. 8, n. 1, p. 1, doi. 10.1186/s40658-021-00394-3
- By:
- Publication type:
- Article
To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 12, p. 3776, doi. 10.1007/s00259-021-05340-0
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga‐SB3 PET/CT‐imaging of primary prostate cancer in therapy‐ naive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
Modeling early radiation DNA damage occurring during [<sup>177</sup>Lu]Lu-DOTA-[Tyr³]octreotate radionuclide therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262610
- By:
- Publication type:
- Article
EANM position paper on the role of radiobiology in nuclear medicine.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 11, p. 3365, doi. 10.1007/s00259-021-05345-9
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga‐SB3 PET/CT‐imaging of primary prostate cancer in therapy‐ naive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Dosimetric evaluation of receptor-heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262122
- By:
- Publication type:
- Article
Modeling early radiation DNA damage occurring during [<sup>177</sup>Lu]Lu-DOTA-[Tyr³]octreotate radionuclide therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262610
- By:
- Publication type:
- Article
Phase I study to assess safety, biodistribution and radiation dosimetry for <sup>89</sup>Zr-girentuximab in patients with renal cell carcinoma.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 10, p. 3277, doi. 10.1007/s00259-021-05271-w
- By:
- Publication type:
- Article